Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Akcea nets $133.7mm via IPO

Executive Summary

After filing back in March, Ionis Pharmaceutical Inc.'s Akcea Therapeutics Inc. netted $133.7mm through an upsized initial public offering of 17.9mm common shares (including the overallotment) at $8 each. It planned to sell 9.6mm shares between $12 and $14. Ionis purchased 3.1mm shares in the IPO and will now own 68.3% of Akcea.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies